Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 55 Greens Farms Road WESTPORT CT 06880 |
Tel: | N/A |
Website: | https://www.biosig.com |
IR: | See website |
Key People | ||
Frederick D. Hrkac President, Principal Executive Officer, Director |
Business Overview |
BioSig Technologies, Inc. is a medical technology company. The Company is focused on commercializing an advanced digital signal processing technology platform to deliver insights to the treatment of cardiovascular arrhythmias. Its product PURE EP System is a non-invasive class II device consisting of a combination of hardware and software designed to provide signal clarity and precision for real-time visualization of intracardiac signals, paving the way for personalized patient care. PURE EP System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated with signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time. |
Financial Overview |
For the fiscal year ended 31 December 2023, BioSig Technologies Inc revenues decreased 94% to $18K. Net loss applicable to common stockholders increased 7% to $29.1M. Revenues reflect Product decrease from $254K to $0K, Service decrease of 44% to $18K. Higher net loss reflects BioSig Technologies Inc segment loss increase of 10% to $29.3M, BioSig AI sciences Inc segment loss increase of 11% to $745K. |
Employees: | 4 as of Apr 15, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $17.23M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.02M as of Dec 31, 2023 |
EBITDA (TTM): | -$28.15M as of Dec 31, 2023 |
Net annual income (TTM): | -$29.05M as of Dec 31, 2023 |
Free cash flow (TTM): | -$17.50M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 11,198,174 as of Apr 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |